drugset / Trial / NCT05148000

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

NCT05148000

Phase 3 Completed 25 enrolled Galderma R&D
NaSingle-groupOpen-labelTreatment

Summary

This study to assess aesthetic improvement following treatment with QM1114-DP.

Timeline

Start
2023-01-23
Primary completion
2023-03-31
Completion
2023-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin Protein / enzyme biologic

Indications